R. Lassalle

3.6k total citations · 1 hit paper
98 papers, 2.4k citations indexed

About

R. Lassalle is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R. Lassalle has authored 98 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Cardiology and Cardiovascular Medicine, 17 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R. Lassalle's work include Atrial Fibrillation Management and Outcomes (16 papers), Drug-Induced Hepatotoxicity and Protection (9 papers) and Antiplatelet Therapy and Cardiovascular Diseases (8 papers). R. Lassalle is often cited by papers focused on Atrial Fibrillation Management and Outcomes (16 papers), Drug-Induced Hepatotoxicity and Protection (9 papers) and Antiplatelet Therapy and Cardiovascular Diseases (8 papers). R. Lassalle collaborates with scholars based in France, Netherlands and United Kingdom. R. Lassalle's co-authors include Nicholas Moore, Patrick Blin, Alexandre Pariente, Mai Duong, Mathiéu Molimard, C. Droz‐Perroteau, Julien Bezin, Marie‐Agnès Bernard, Karine Titier and Bernard Bégaud and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

R. Lassalle

91 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology

2017 398 citations Mai Duong, R. Lassalle et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Lassalle France	22	523	423	404	281	260	98	2.4k
William E. Smoyer United States	36	294 0.6×	399 0.9×	435 1.1×	138 0.5×	691 2.7×	116	3.5k
Der‐Cherng Tarng Taiwan	37	565 1.1×	337 0.8×	519 1.3×	464 1.7×	923 3.5×	218	4.7k
Gerald A. Faich United States	29	468 0.9×	288 0.7×	218 0.5×	341 1.2×	279 1.1×	75	5.0k
Ho Jun Chin South Korea	36	241 0.5×	128 0.3×	510 1.3×	428 1.5×	581 2.2×	188	4.0k
Aleix Cases Spain	36	1.2k 2.3×	334 0.8×	585 1.4×	449 1.6×	822 3.2×	214	4.2k
Mary T. Brophy United States	28	243 0.5×	131 0.3×	436 1.1×	172 0.6×	285 1.1×	114	3.3k
Dong‐Wan Chae South Korea	35	250 0.5×	109 0.3×	514 1.3×	348 1.2×	668 2.6×	179	4.0k
Ronen Loebstein Israel	31	251 0.5×	166 0.4×	146 0.4×	110 0.4×	230 0.9×	75	3.0k
Jean‐Luc Reny Switzerland	32	950 1.8×	193 0.5×	304 0.8×	137 0.5×	370 1.4×	157	3.6k
Ionuţ Nistor Romania	31	276 0.5×	83 0.2×	379 0.9×	377 1.3×	229 0.9×	92	2.9k

Countries citing papers authored by R. Lassalle

Since Specialization

Citations

This map shows the geographic impact of R. Lassalle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Lassalle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Lassalle more than expected).

Fields of papers citing papers by R. Lassalle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Lassalle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Lassalle. The network helps show where R. Lassalle may publish in the future.

Co-authorship network of co-authors of R. Lassalle

This figure shows the co-authorship network connecting the top 25 collaborators of R. Lassalle. A scholar is included among the top collaborators of R. Lassalle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Lassalle. R. Lassalle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caimmi, Davide, Abdelilah Abouelfath, R. Lassalle, et al.. (2025). Patient-perceived benefits of sublingual allergen immunotherapy: Design of the ERAPP study. 5. 100033–100033.

Blin, Patrick, Michaël Joubert, Patrick Jourdain, et al.. (2024). Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database. Cardiovascular Diabetology. 23(1). 22–22. 3 indexed citations

Jové, Jérémy, Marine Gross‐Goupil, Patrick Blin, et al.. (2023). Clustering of prostate cancer healthcare pathways in the French National Healthcare database. SHILAP Revista de lepidopterología. 2(1). 52–64. 5 indexed citations

Bosco‐Lévy, Pauline, Karine Briot, Nadia Mehsen-Cêtre, et al.. (2023). Real‐World Effectiveness of Osteoporosis Medications in France: A Nationwide Cohort Study. JBMR Plus. 7(9). e10789–e10789. 1 indexed citations

Bosco‐Lévy, Pauline, Marc Debouverie, Bruno Brochet, et al.. (2021). Comparative effectiveness of dimethyl fumarate in multiple sclerosis. British Journal of Clinical Pharmacology. 88(3). 1268–1278. 9 indexed citations

Tan, Eng Hooi, Annika M. Jödicke, Mees Mosseveld, et al.. (2021). The impact of COVID-19 on population-level drug utilization of alendronate. Osteoporosis International. 1 indexed citations

Sénéschal, Julien, H. Maillard, Thierry Passeron, et al.. (2021). Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study. Journal of Investigative Dermatology. 141(7). 1728–1734. 23 indexed citations

Bénard, Antoine, et al.. (2021). Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response. Value in Health. 24(5). 683–690. 3 indexed citations

Bosco‐Lévy, Pauline, Patrick Blin, R. Lassalle, et al.. (2020). PND25 Cost-Consequence Analysis of Dimethyl Fumarate Versus Other Disease-Modifying Therapies in Multiple Sclerosis: A French Cohort Study with Snds National Claims Database in France. Value in Health. 23. S626–S626. 1 indexed citations

10.

Moore, Nicholas, Laurent Fauchier, Marie‐Agnès Bernard, et al.. (2018). Abstract 14523: Two-Year Benefit-Risk of Standard and Reduced Doses of Rivaroxaban versus Vitamin-K Antagonists in Non-Valvular Atrial Fibrillation: A Cohort Study in the French Nationwide Claims Database. Circulation. 1 indexed citations

11.

Moore, Nicholas, R. Lassalle, Mai Duong, et al.. (2018). Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System. Drug Safety. 42(4). 559–572. 13 indexed citations

12.

Blin, Patrick, C. Dureau‐Pournin, Jacques Bénichou, et al.. (2018). Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database. Atherosclerosis. 281. 98–106. 11 indexed citations

13.

Fauchier, Laurent, Patrick Blin, Marie‐Agnès Bernard, et al.. (2017). Abstract 20559: Effectiveness and Safety of Rivaroxaban 15 mg Compared With Vitamin K Antagonists in Very Elderly Patients With Atrial Fibrillation, a Matched Cohort Study in the French Nationwide Claims Database SNIIRAM. Circulation. 1 indexed citations

14.

Girodet, Pierre‐Olivier, Benoît Allard, Matthieu Thumerel, et al.. (2015). Bronchial Smooth Muscle Remodeling in Nonsevere Asthma. American Journal of Respiratory and Critical Care Medicine. 193(6). 627–633. 40 indexed citations

15.

Blin, Patrick, S. Lamarque, Marie‐Christine Bernard, et al.. (2014). Misuse, Abuse, and Diversion of instanyl® (Fentanyl Nasal Spray) in France. Value in Health. 17(7). A649–A649. 1 indexed citations

16.

Guelfucci, Florent, E. Clay, Samuel Aballéa, et al.. (2013). Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France. BMC Endocrine Disorders. 13(1). 15–15. 7 indexed citations

17.

Fourrier‐Réglat, Annie, Pernelle Noïze, Thierry Façon, et al.. (2013). Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study. Leukemia & lymphoma. 55(4). 848–854. 9 indexed citations

18.

Berke, Bénédicte, Catherine Chèze, Raphaële Le Garrec, et al.. (2012). Preventive and curative effect of Trigonella foenum-graecum L. seeds in C57BL/6J models of type 2 diabetes induced by high-fat diet. Journal of Ethnopharmacology. 142(2). 516–522. 53 indexed citations

19.

Smith, Denis, Eric Terrebonne, Jean‐Frédéric Blanc, et al.. (2011). Chemotherapy and targeted agents for colorectal cancer in a real‐life setting anticipate guidelines: the COLCHIC cohort study. Fundamental and Clinical Pharmacology. 27(1). 113–119. 4 indexed citations

20.

Picard, Stéphane, Karine Titier, Gabriel Étienne, et al.. (2006). Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 109(8). 3496–3499. 468 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact